Trending NewsTrending NewsNYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $9.76 -0.12 (-1.16%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$9.76 -0.01 (-0.10%) As of 06/20/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Organon & Co. Stock (NYSE:OGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organon & Co. alerts:Sign Up Key Stats Today's Range$9.60▼$9.8850-Day Range$8.05▼$13.2152-Week Range$8.01▼$23.10Volume4.77 million shsAverage Volume3.46 million shsMarket Capitalization$2.54 billionP/E Ratio3.39Dividend Yield0.82%Price Target$18.00Consensus RatingModerate Buy Company OverviewOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Read More… Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreOGN MarketRank™: Organon & Co. scored higher than 94% of companies evaluated by MarketBeat, and ranked 169th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOrganon & Co. has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageOrganon & Co. has only been the subject of 4 research reports in the past 90 days.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth1.63% Earnings GrowthEarnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 3.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 3.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.43.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 1.03. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioOrganon & Co. has a P/B Ratio of 5.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Organon & Co.'s valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.75% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently increased by 9.59%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldOrganon & Co. has a dividend yield of 0.81%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 2.78%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.14% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. Sustainability and ESG3.7 / 5Environmental Score-2.37 Percentage of Shares Shorted6.75% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently increased by 9.59%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.15 News SentimentOrganon & Co. has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Organon & Co. this week, compared to 10 articles on an average week.Search InterestOnly 17 people have searched for OGN on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have bought more of their company's stock than they have sold. Specifically, they have bought $902,430.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.96% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address OGN Stock News HeadlinesORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 20 at 10:50 PM | prnewswire.comOGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud LawsuitJune 20 at 5:18 PM | prnewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 21, 2025 | Porter & Company (Ad)OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 20 at 4:00 PM | globenewswire.comDeadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJune 20 at 12:35 PM | globenewswire.comFaruqi & Faruqi Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGNJune 20 at 11:22 AM | prnewswire.comOGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)June 20 at 9:06 AM | globenewswire.comLevi & Korsinsky Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGNJune 20 at 9:00 AM | prnewswire.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $14.92 at the beginning of the year. Since then, OGN stock has decreased by 34.6% and is now trading at $9.7650. View the best growth stocks for 2025 here. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) announced its quarterly earnings data on Thursday, May, 1st. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.13. Organon & Co.'s revenue was down 6.7% compared to the same quarter last year. Read the conference call transcript. Who are Organon & Co.'s major shareholders? Organon & Co.'s top institutional investors include Vanguard Group Inc. (11.43%), Massachusetts Financial Services Co. MA (4.12%), LSV Asset Management (3.07%) and Sound Shore Management Inc. CT (1.91%). Insiders that own company stock include Kevin Ali, Matthew M Walsh, Kirke Weaver and Daniel Karp. View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM). Company Calendar Last Earnings5/01/2025Record date for 6/12 Dividend5/12/2025Ex-Dividend for 6/12 Dividend5/12/2025Dividend Payable6/12/2025Today6/21/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone551-430-6900FaxN/AEmployees4,000Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$24.00 Low Stock Price Target$10.00 Potential Upside/Downside+84.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$2.88 Trailing P/E Ratio3.39 Forward P/E Ratio2.65 P/E Growth1.03Net Income$864 million Net Margins11.92% Pretax Margin10.68% Return on Equity227.43% Return on Assets7.34% Debt Debt-to-Equity Ratio16.49 Current Ratio1.67 Quick Ratio1.15 Sales & Book Value Annual Sales$6.40 billion Price / Sales0.40 Cash Flow$4.86 per share Price / Cash Flow2.01 Book Value$1.83 per share Price / Book5.34Miscellaneous Outstanding Shares259,960,000Free Float254,861,000Market Cap$2.54 billion OptionableNot Optionable Beta0.58 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSE:OGN) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.